Equities analysts expect Omnicell, Inc. (NASDAQ:OMCL) to report sales of $283.82 million for the current quarter, according to Zacks. Two analysts have made estimates for Omnicell’s earnings, with the highest sales estimate coming in at $285.38 million and the lowest estimate coming in at $282.26 million. Omnicell reported sales of $213.70 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 32.8%. The firm is expected to issue its next earnings report before the market opens on Tuesday, November 2nd.
According to Zacks, analysts expect that Omnicell will report full year sales of $1.11 billion for the current fiscal year. For the next year, analysts expect that the firm will post sales of $1.26 billion, with estimates ranging from $1.25 billion to $1.28 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Omnicell.
Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, July 29th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.42. Omnicell had a net margin of 6.05% and a return on equity of 11.06%. The company had revenue of $272.74 million for the quarter, compared to analysts’ expectations of $267.20 million.
In other news, CFO Peter J. Kuipers sold 11,500 shares of the stock in a transaction on Friday, August 6th. The stock was sold at an average price of $157.88, for a total value of $1,815,620.00. Following the completion of the transaction, the chief financial officer now owns 59,812 shares of the company’s stock, valued at $9,443,118.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James T. Judson sold 4,984 shares of the firm’s stock in a transaction dated Monday, August 23rd. The shares were sold at an average price of $153.00, for a total value of $762,552.00. Following the transaction, the director now directly owns 23,320 shares of the company’s stock, valued at approximately $3,567,960. The disclosure for this sale can be found here. Insiders have sold a total of 65,048 shares of company stock valued at $10,001,198 in the last ninety days. Corporate insiders own 2.63% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Macquarie Group Ltd. increased its holdings in shares of Omnicell by 108.8% during the 2nd quarter. Macquarie Group Ltd. now owns 1,019,025 shares of the company’s stock valued at $154,332,000 after acquiring an additional 530,922 shares during the last quarter. Clearbridge Investments LLC grew its holdings in shares of Omnicell by 31.6% during the 2nd quarter. Clearbridge Investments LLC now owns 1,086,808 shares of the company’s stock worth $164,597,000 after purchasing an additional 260,868 shares in the last quarter. APG Asset Management N.V. acquired a new stake in shares of Omnicell during the 2nd quarter worth approximately $33,077,000. Vanguard Group Inc. lifted its position in shares of Omnicell by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,661,303 shares of the company’s stock worth $705,954,000 after buying an additional 155,379 shares during the period. Finally, Neuberger Berman Group LLC lifted its position in shares of Omnicell by 16.0% during the 2nd quarter. Neuberger Berman Group LLC now owns 1,066,047 shares of the company’s stock worth $161,453,000 after buying an additional 147,101 shares during the period.
OMCL opened at $167.29 on Friday. The stock has a market capitalization of $7.27 billion, a price-to-earnings ratio of 128.68, a PEG ratio of 4.97 and a beta of 1.04. The company has a fifty day moving average of $155.97 and a 200 day moving average of $147.36. Omnicell has a fifty-two week low of $82.01 and a fifty-two week high of $168.69. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.78 and a current ratio of 3.10.
Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.
Read More: What is a capital gain?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.